|Dr. Richard A. Miller||Co-Founder, Pres, CEO & Chairman||305.96k||N/A||1951|
|Dr. Joseph J. Buggy||Co-Founder & Exec. VP of Discovery Research||143.57k||N/A||1967|
|Mr. Leiv Lea||Chief Financial Officer||324.12k||N/A||1954|
|Dr. William Benton Jones||Sr. VP of Pharmaceutical Devel.||N/A||N/A||1966|
|Mr. Daniel W. Hunt J.D.||Sr. VP & Chief Bus. Officer||N/A||N/A||1962|
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Corvus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.